Synaptogenix (SNPX) Competitors

Affimed (NASDAQ:AFMD) and Synaptogenix (NASDAQ:SNPX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership, community ranking and profitability.

Which has preferable valuation & earnings, AFMD or SNPX?

Synaptogenix has lower revenue, but higher earnings than Affimed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Affimed	$877K	14.34	-$114.66M	N/A	N/A
Synaptogenix	N/A	N/A	-$6.04M	N/A	N/A

Is AFMD or SNPX more profitable?

Synaptogenix has a net margin of 0.00% compared to Affimed's net margin of -7,836.26%. Synaptogenix's return on equity of -42.14% beat Affimed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Affimed	-7,836.26%	-193.84%	-107.24%
Synaptogenix	N/A	-42.14%	-29.42%

Which has more volatility & risk, AFMD or SNPX?

Affimed has a beta of 2.22, suggesting that its stock price is 122% more volatile than the S&P 500. Comparatively, Synaptogenix has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500.

Do institutionals and insiders hold more shares of AFMD or SNPX?

30.8% of Affimed shares are held by institutional investors. Comparatively, 10.3% of Synaptogenix shares are held by institutional investors. 3.8% of Affimed shares are held by insiders. Comparatively, 2.7% of Synaptogenix shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Do analysts rate AFMD or SNPX?

Affimed presently has a consensus price target of $13.50, suggesting a potential upside of 1,628.33%. Synaptogenix has a consensus price target of $14.00, suggesting a potential upside of 422.39%. Given Affimed's higher probable upside, equities analysts clearly believe Affimed is more favorable than Synaptogenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Affimed	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Synaptogenix	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community prefer AFMD or SNPX?

Affimed received 437 more outperform votes than Synaptogenix when rated by MarketBeat users. Likewise, 70.24% of users gave Affimed an outperform vote while only 66.67% of users gave Synaptogenix an outperform vote.

Company	Underperform	Outperform
Affimed	Outperform Votes 439 70.24%	Underperform Votes 186 29.76%
Synaptogenix	Outperform Votes 2 66.67%	Underperform Votes 1 33.33%

Does the media favor AFMD or SNPX?

In the previous week, Affimed had 2 more articles in the media than Synaptogenix. MarketBeat recorded 4 mentions for Affimed and 2 mentions for Synaptogenix. Affimed's average media sentiment score of 0.90 beat Synaptogenix's score of -0.56 indicating that Affimed is being referred to more favorably in the media.

Company	Overall Sentiment
Affimed	Positive
Synaptogenix	Negative

Summary

Affimed beats Synaptogenix on 10 of the 15 factors compared between the two stocks.